Strados Labs, a medical technology company focused on smart sensors, has secured the CE Mark approval for its RESP smart sensor platform to aid the early detection of respiratory diseases.

At present, there are no convenient ways to remotely capture abnormal patient lung sounds and patterns, said the medical technology company.

Strados said that its RESP smart sensor platform would help capture, lung sounds remotely, across different healthcare settings to identify abnormal breathing patterns anywhere, anytime.

In December last year, the US Food and Drug Administration (FDA) granted Class II 510(k) approval for the RESP platform for measuring, recording and analysing lung sounds remotely.

Strados Labs co-founder and CEO Nick Delmonico said: “Being granted this CE Mark in less than a year from receiving our FDA Class II 510(k) clearance for our RESP Smart Sensor Platform is a significant achievement for Strados.

“Our large pharma clients have many trials underway or planned in Europe, and this allows us to work with our customers on global research projects and in international markets.

“I’m incredibly proud of our team and how hard they’ve worked to get us to this next significant milestone.”

RESP is a cloud-based smart sensor platform that aids early and remote detection of important changes in lung acoustics and respiratory patterns for patients.

The platform is said to provide a cost-effective, non-invasive, and wireless solution to clinicians, which easily integrates with existing clinical workflows.

RESP is also used in clinical trials to capture lung sound measurements data as primary and exploratory endpoints and help predict life-threatening pulmonary failure events.

The company claimed that it is working together with pharmaceutical companies and research organisations to capture lung sound measurements for clinical trials of RESP.

Strados Labs is a medical technology company focused on smart sensors and AI to provide early detection and predictions of worsening diseases.

The company is currently developing other smart sensor platforms to support and address other chronic diseases, along with chronic disease management.

Delmonico added: “With this CE Mark, we will now be able to market and sell our RESP Smart Sensor Platform in EU member countries that accept CE marked medical devices.

“This opens the door for us to truly impact the lives of so many individuals in other parts of the world who need our respiratory technology. Europe’s adoption of smart sensor technology is outpacing the US.”